Shield Therapeutics (LSE:STX) reported unaudited revenues of around $50m for 2025, reflecting strong commercial momentum driven primarily by its U.S. franchise. Sales of ACCRUFeR in the United States rose 56% year on year to approximately $46m, supported by a 21% increase in average net selling price and a 33% rise in total prescriptions to about 199,000.
The acceleration in demand translated into a key financial milestone, with the company delivering positive operating cash flow in the fourth quarter. Shield ended the year with cash and cash equivalents of $11.6m, underpinned by record quarterly prescription volumes and a strengthened balance sheet.
On the back of this progress, management now expects to deliver an operating profit in 2026, marking a shift towards sustainable, self-funded growth. The company believes this positions it more competitively within the iron deficiency and iron deficiency anaemia treatment market as scale benefits and pricing momentum continue to build.
While technical indicators and recent corporate developments are supportive, the overall outlook remains balanced by ongoing financial and valuation risks. Nevertheless, the move to cash flow positivity and the prospect of profitability represent important steps forward for the business.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on the treatment of iron deficiency and iron deficiency anaemia. Its flagship product, ACCRUFeR/FeRACCRU (ferric maltol), is the first and only FDA-approved oral iron therapy for ID/IDA in the United States. Shield addresses a large market opportunity through its exclusive U.S. collaboration with Viatris and a network of licensing partners across Europe, Asia-Pacific and other international markets, with patent protection extending into the mid-2030s.
Leave a Reply